Crinetics Pharmaceuticals (CRNX) Income towards Parent Company (2017 - 2026)

Crinetics Pharmaceuticals' Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$249.3 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 357.58% year-over-year to -$249.3 million; the TTM figure through Mar 2026 stood at -$386.4 million (down 2982.01% YoY), while the FY2025 annual figure was -$465.3 million, down 56.18% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$249.3 million, down from -$122.6 million in the prior quarter.
• The five-year high for Income towards Parent Company was $115.6 million in Q2 2025, with the low at -$362.8 million in Q4 2023.
• The 5-year median for Income towards Parent Company is $42.4 million (2022), against an average of -$20.8 million.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company soared 124.39% in 2022, then slumped 906.31% in 2023.
• Crinetics Pharmaceuticals' Income towards Parent Company stood at $45.0 million in 2022, then plunged by 906.31% to -$362.8 million in 2023, then soared by 77.78% to -$80.6 million in 2024, then plunged by 52.16% to -$122.6 million in 2025, then sank by 103.26% to -$249.3 million in 2026.
• Business Quant data shows CRNX's Income towards Parent Company at -$249.3 million in Q1 2026, -$122.6 million in Q4 2025, and -$130.1 million in Q3 2025.